November 17th, 2013
Brainstorming the Abstracts Submission Process at AHA.13
Saurav Chatterjee, MD
A fellow discusses many of the ideas arising from a small but provocative gathering.
November 17th, 2013
Clinical Lipidology Becomes a Controversial Field
Reva Balakrishnan, MD, MPH
This cardiology Fellow finds heat and light at a lively session on the new prevention guidelines.
November 17th, 2013
What Council Involvement Can Add
John Ryan, MD
The Associate Editor of CardioExchange explains the myriad benefits of AHA council involvement.
November 17th, 2013
Remaking the Heart: Stem Cells, Patches, Scaffolds, and More
Vimal Ramjee, MD
Which advance in regenerative cardiovascular biology has the best chance of being translated into a clinical treatment? A cardiology Fellow ponders cutting-edge science presentations at AHA.13.
November 17th, 2013
Early-Career Sessions at AHA 2013: Pearls, Personal Insights, and Powerhouse Presentations
Saurav Chatterjee, MD
Another perspective on the fellows-in-training sessions from the first day of AHA 2013
November 16th, 2013
Advice for Fellows-in-Training: Focus, Persistence Are Keys
Reva Balakrishnan, MD, MPH
One of CardioExchange’s blogging fellows shares her highlights of the AHA’s fellows-in-training sessions.
November 16th, 2013
Becoming a Cardiovascular Investigator – Treading in Deep Waters, or a Sure Shot Toward a Successful Future?
Vimal Ramjee, MD
One of CardioExchange’s blogging fellows asks the question: Is it possible to succeed as a young investigator in the current funding climate?
November 16th, 2013
A Critical Time for Health Research?
Siqin Ye, MD
A Cardiology fellow shares his thoughts on some key issues in healthcare as he prepares for the 2013 AHA Scientific Sessions.
November 15th, 2013
Hypertension Treatment Algorithm Fills in for Missing Guideline
Larry Husten, PHD
When the AHA and the ACC released four updated clinical guidelines earlier this week, a fifth document, the hypertension guideline, was conspicuous by its absence. According to the AHA and the ACC, the authors of the hypertension document have chosen to publish it independently. (No word has yet emerged about their reasons for doing so […]
November 12th, 2013
Promising GSK Heart Drug Misses Primary Endpoint in 15,000-Patient Trial
Larry Husten, PHD
GlaxoSmithKline announced today that the first of two pivotal phase 3 trials with a new drug, darapladib, had failed to meet its primary endpoint. Full results of the trial will be presented at a scientific meeting. The STABILITY trial (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) tested the effect of darapladib, an investigational Lp-PLA2 inhibitor, in more […]